Ergänzende Referenzen zu RLY-4008, dem ersten hochselektiven FGFR2-Inhibitor mit Aktivität gegen FGFR2-Veränderungen und Resistenzmutationen

Subbiah et al. (Mon,) haben diese Fragestellung untersucht.

www.synapsesocial.com/papers/68e586b5b6db643587522f0d — DOI: https://doi.org/10.1158/2159-8290.27025766

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations· 2024
2. Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations· 2024
3. Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations· 2024
4. Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations· 2024
5. Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations· 2024